Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura.

ML, Sargentini-Maier; Decker P, De; C, Tersteeg; J, Canvin; F, Callewaert; Winter H, De

doi:10.1080/17512433.2019.1607293

Public

Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura.

Shared by NobleBlocks on Apr 28, 2019 • 12:00 AM UTC

Authors:

Sargentini-Maier ML

De Decker P

Tersteeg C

Abstract

<b>Introduction</b>: Caplacizumab is a humanized anti-von Willebrand Factor (vWF) Nanobody® for the treatment of acquired Thrombotic Thrombocytopenic Purpura (aTTP). Caplacizumab targets the A1-domain of vWF, inhibiting the interaction between vWF and platelets. Clinical studies conducted in aTTP pa...

Subject

Pharmacokinetics

vWF

Pharmacodynamics

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!